CURRENTLY
ENROLLING TRIALS
|
HIV MEDICATION TRIALS
|
BASIC
CRITERIA: HIV POSITIVE, NEVER RECEIVED HIV MEDICATION, CD4 50-400
MEN OR 50-250 WOMEN, VIRAL LOAD IS EQUAL OR GREATER THAN 1000
VERVE BI 1100.1486 "A
double-blind, randomized, double-dummy, parallel group active control
trial to evaluate the anti-viral efficacy of 400mg QD Nevirapine
extended release formulation in comparison to 200mg BID Nevirapine
immediate release in combination with Truvada in anti-retroviral
therapy naive HIV1 infected patients.
For information, please email
or call us at 305-576-1234
|
HIV TREATMENT
TRIALS
|
BASIC CRITERIA: CURRENTLY TAKING
KALETRA, VIRAL LOAD IS LESS THAN 50 FOR PAST 3 MONTHS, NOT TAKING
CHOLESTEROL MEDICATIONS, NO HISTORY OF CORONARY ARTERY DISEASE
KALETRA MK
0518-033 " A multi-center, randomized, double-blind,
active controlled study to evaluate the safety and ARV activitiy of MK
0518 versus KALETRA in HIV infected patients switched from a stable
KALETRA based regiment.
For information, please email
or call us at 305-576-1234
|
ONGOING
HIV
TRIALS (NOT ENROLLING)
|
Merck Protocol
021-00
A multi-center, double-blind, randomized, placebo-controlled
Study to Evaluate the Safety and Antiretroviral Activity of MK
0518 Versus Efavirenz in Treatment Naive HIV Infected Patients,
Each in Combination with TRUVADA. |
Merck
Protocol 023-00
A multi-center, double-blind, randomized, placebo-controlled Phase II
Proof-of-Concept Study to Evaluate the
Safety and Efficacy of a 3-Dose Regimen of the Merck Adenovirus
Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd5 HIV-1 gag/pol/net) in
Adults at High Risk of HIV-1 Infection. |
Merck
Protocol 027-00
A Phase IIa Dose - Refinement study of
the safety and
Immunogenicity of a 3-Dose regimen of the Merck Adenovirus Serotype 5
HIV - 1 gag/pol/nef Vaccine in Healthy Adults. |
2003 -
Present
Protocol 016-02 - A
Phase I Dose-Ranging study of the safety, tolerability, and
Immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1
gag/pol/nef? in a Prime-Boose Regimen in Healthy Adults.
|
2001 -
Present
A Phase III
multi-center, randomized study of the biological and clinical efficacy
of subcutaneous recombinant, Human Interluekin-2 in HIV- infected
Patients with Low CD4+ Counts under Active Antiretroviral Therapy
(SILCAAT) "IL-2".
|
